DYAI
MaterialsDyadic International Inc DE
$0.76-0.01 (-1.30%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving DYAI Today?
No stock-specific AI insight has been generated for DYAI yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$28M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume17K
Avg Volume (10D)—
Shares Outstanding36.4M
DYAI News
20 articles- Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026Yahoo Finance·Apr 29, 2026
- DYAI: Introducing AlbuFree DXYahoo Finance·Mar 30, 2026
- Analysts Expect Breakeven For Dyadic International, Inc. (NASDAQ:DYAI) Before LongYahoo Finance·Mar 28, 2026
- Dyadic International Inc (DYAI) Q4 2025 Earnings Call Highlights: Navigating Transition with ...Yahoo Finance·Mar 26, 2026
- Dyadic International, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 26, 2026
- Dyadic (DYAI) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 25, 2026
- Dyadic Announces 2025 Financial Results and Highlights Recent Company ProgressYahoo Finance·Mar 25, 2026
- Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT BioservicesYahoo Finance·Mar 16, 2026
- Life Sciences Virtual Investor Forum Presentations Now Available for Online ViewingYahoo Finance·Mar 13, 2026
- Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026Yahoo Finance·Mar 11, 2026
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thYahoo Finance·Mar 10, 2026
- Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)Yahoo Finance·Mar 4, 2026
- Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development MilestoneYahoo Finance·Mar 2, 2026
- Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human AlbuminYahoo Finance·Feb 17, 2026
- DYAI: Layers of Commercialization AgreementsYahoo Finance·Dec 22, 2025
- Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial MarketsYahoo Finance·Dec 17, 2025
- Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media ProteinsYahoo Finance·Dec 15, 2025
- Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025Yahoo Finance·Dec 8, 2025
- iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025Yahoo Finance·Dec 1, 2025
- Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition MarketsYahoo Finance·Dec 1, 2025
All 20 articles loaded
Price Data
Open$0.76
Previous Close$0.77
Day High$0.78
Day Low$0.76
52 Week High—
52 Week Low—
Fundamentals
Market Cap$28M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume17K
Avg Volume (10D)—
Shares Outstanding36.4M
About Dyadic International Inc DE
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—